((自动化翻译由路透提供，请见免责声明 ))
11月11日 - ** 生物技术公司 Novavax 的 股价盘前上涨 11%，报 9.90 美元
** 公司称美国食品和药物管理局已经解除了对NVAX公司COVID-流感疫苗和独立流感疫苗后期研究的临床搁置。
** 由于中期研究参与者最初报告称肌肉控制神经细胞受到了一些损伤，因此该研究被搁置。
** Novavax 称已向 FDA 提交了补充信息，其中包括该参与者的症状已转变为肌萎缩性脊髓侧索硬化症，这是一种可导致进行性瘫痪和死亡的疾病。
** 该公司称，其评估结果表明，该受试者的病症与其联合疫苗无关
** Novavax公司计划尽快恢复后期试验的注册工作
** 截至上次收盘，NVAX 的股价今年几乎翻了一番
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.